Drug Profile
Parkinson's disease gene therapy - Gene Therapy Research Institution
Latest Information Update: 28 Mar 2019
Price :
$50
*
At a glance
- Originator Gene Therapy Research Institution
- Class Antiparkinsonians; Gene therapies
- Mechanism of Action Dopamine release stimulants; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 28 Mar 2019 No recent reports of development identified for clinical-Phase-Unknown development in Parkinson's-disease in Japan (Parenteral)
- 10 Aug 2017 Gene Therapy Research Institution plans phase III trials in 2021 (Gene Therapy Research Institution pipeline, August 2017)
- 09 Aug 2017 Gene Therapy Research Institution plans phase I/II trials in 2019 (Gene Therapy Research Institution pipeline, August 2017)